ImmuPharma PLC is a pharmaceutical company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. The company’s most advanced drug candidate recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and “Fast Track” designation. ImmuPharma is led by a commercially focused Board and management team with extensive experience.